Publications
2025
Hieromnimon HM, Dolezal J, Doytcheva K, Howard FM, Kochanny S, Zhang Z, Grossman RL, Tanager K, Wang C, Kather JN, Izumchenko E, Cipriani NA, Fertig EJ, Pearson AT, Riesenfeld SJ. Building digital histology models of transcriptional tumor programs with generative deep learning for pathology-based precision medicine. Genome Med. 17, 87 (2025). doi: 10.1186/s13073-025-01502-z
Hieromnimon HM, Trzcinska A, Wen FT, Howard FM, Dolezal JM, Dyer E, Kochanny S, Schulte JJ, Wang C, Chen H, Chin J, Blair E, Agrawal N, Rosenberg A, Vokes E, Katipally R, Juloori A, Izumchenko E, Lingen MW, Cipriani N, Jalaly JB, Basu D, Riesenfeld SJ, Pearson A. Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas. Oral Oncology. 163, 107207 (2025). doi: 10.1016/j.oraloncology.2025.107207
2024
Howard FM, Hieromnimon HM, Ramesh S, Dolezal J, Kochanny S, Zhang Q, Brad Feiger, Peterson J, Fan C, Perou CM, Vickery J, Sullivan M, Cole K, Khramtsova G, Pearson A. Generative adversarial networks accurately reconstruct pan-cancer histology from pathologic, genomic, and radiographic latent features.Sci. Adv.10, eadq0856 (2024). doi: 10.1126/sciadv.adq0856
2023
Chaudagar K, Hieromnimon HM, Kelley A, Labadie B, Shafran J, Rameshbabu S, Drovetsky C, Bynoe K, Solanki A, Markiewicz E, Fan X, Loda M, Patnaik A. Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis. Clin Cancer Res. 2023 Sep 18. doi: 10.1158/1078-0432.CCR-23-1441. Epub ahead of print. PMID: 37721526.
Dolezal JM, Wolk R, Hieromnimon HM, Howard FM, Srisuwananukorn A, Karpeyev D, Ramesh S, Kochanny S, Kwon JW, Agni M, Simon RC, Desai C, Kherallah R, Nguyen TD, Schulte JJ, Cole K, Khramtsova G, Garassino MC, Husain AN, Li H, Grossman R, Cipriani NA, Pearson AT. Deep learning generates synthetic cancer histology for explainability and education. npj Precis. Onc. 7, 49 (2023). https://doi.org/10.1038/s41698-023-00399-4
Hieromnimon HM, Dolezal J, Doytcheva K, Howard FM, Kochanny S, Zhang Z, Grossman RL, Tanager K, Wang C, Kather JN, Izumchenko E, Cipriani NA, Fertig EJ, Pearson AT, Riesenfeld SJ. Latent transcriptional programs reveal histology-encoded tumor features spanning tissue origins. bioRxiv 2023.03.22.533810; doi: https://doi.org/10.1101/2023.03.22.533810
Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, Hasan R, Shafran J, Kelley A, Apostolov E, El-Aryani G, Rameshbabu S, Loyd M, Bynoe K, Drovetsky C, Solanki A, Markiewicz E, Zamora M, Fan X, Sykes D, Swarbrick A, Schürer S, Patnaik A. Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer. Clin Cancer Res CCR-22-3350, (2023). https://doi.org/10.1158/1078-0432.CCR-22-3350
2022
Hieromnimon, HM, Pearson, AT. Ovarian cancer through a multi-modal lens. Nat Cancer 3, 662–664 (2022). https://doi.org/10.1038/s43018-022-00397-8
2021
Chaudagar KK, Landon-Brace N, Solanki A, Hieromnimon HM, Hegermiller E, Li W, Shao Y, Joseph J, Wilkins DJ, Bynoe KM, Li XL, Clohessy JG, Ullas S, Karp JM, Patnaik A. Cabozantinib Unlocks Efficient In Vivo Targeted Delivery of Neutrophil-Loaded Nanoparticles into Murine Prostate Tumors. Mol Cancer Ther. 2021 Feb;20(2):438-449. doi: 10.1158/1535-7163.MCT-20-0167. Epub 2020 Dec 4. PMID: 33277441.
Abstracts
2025
Li A, Torcasso M, Woodard A, Hieromnimon HM, Dolezal J, Abraham R, Clark MR, Zha Y, Pearson AT, Howard FM. Abstract P2-02-19: Virtual Multiplex Immunofluorescence Identifies Lymphocyte Subsets Predictive of Response to Neoadjuvant Therapy. Clin Cancer Res. 31 (12_Supplement), P2–02–19 (2025). doi: 10.1158/1557-3265.SABCS24-P2-02-19
Hieromnimon HM, Miskovic V, Sacco M, Ferrarin A, Mazzeo L, Spagnoletti A, Ganzinelli M, Silvestri C, Provenzano L, Proto C, Peled N, Felip E, Linardou H, Reck M, Trovo F, Lo Russo G, Garassino MC, Riesenfeld SJ, Pearson AT, Prelaj A. Abstract A058: Multimodal generative AI jointly learns pathology and clinical data to synthesize a multinational lung cancer cohort. Clin Cancer Res. 31 (13_Supplement), A058 (2025). doi: 10.1158/1557-3265.AIMACHINE-A058
Hieromnimon HM, Trzcinska A, Wen F, Howard FM, Dolezal JM, Dyer E, Kochanny S, Schulte J, Wang C, Chen H, Chin J, Blair E, Agrawal N, Rosenberg A, Vokes E, Katipally R, Juloori A, Izumchenko E, Lingen MW, Cipriani N, Jalaly JB, Basu D, Riesenfeld SJ, Pearson AT. Abstract 2471: Interpretable HPV detection in head and neck cancer using foundation models and synthetic digital pathology. Cancer Res. 85 (8_Supplement_1), 2471 (2025). doi: 10.1158/1538-7445.AM2025-2471
2023
Chaudagar, K; Hieromnimon, HM.; Kelley, A; Labadie, B; Shafran, J; Rameshbabu, S; et al. (2023). Data from Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis. American Association for Cancer Research. Collection. https://doi.org/10.1158/1078-0432.c.6960647.v1
2020
Patnaik A, Duttagupta P, Chaudagar K, Alter R, Hieromnimon HM, Szmulewitz RZ, Fleming GF, Stadler WM. A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology 2020 38:6_suppl, TPS270-TPS270
